Blueshift Asset Management’s 10x Genomics TXG Stock Holding History
Bought
Maintained
Sold
Other funds holding TXG
AIM
NAMA
Blueshift Asset Management's TXG Position: Q2 2025 in Review
Blueshift Asset Management sold out of 10x Genomics (TXG) in Q2 2025, closing a stake of 10,840 shares — an estimated $94.6K sold.
Blueshift Asset Management first reported a position in TXG in Q1 2021 and held it in 3 quarters. The position peaked at $2.37M in Q2 2021. 297 funds tracked by Wall St. Rank hold TXG as of Q2 2025.
- Blueshift Asset Management reported no remaining 10x Genomics position as of Q2 2025 after selling out during the quarter.
- Blueshift Asset Management sold 10,840 10x Genomics shares in Q2 2025, an estimated $94.6K.
- Blueshift Asset Management first reported a position in 10x Genomics in Q1 2021 and held it in 3 quarters.
- Blueshift Asset Management's 10x Genomics position peaked at $2.37M in Q2 2021.
- 297 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2025.
Based on Blueshift Asset Management's 13F filing for Q2 2025, filed 13 Aug 2025.